UNSPSC 51422332: Dexamethasone acefurate

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H33FO8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W4N6E1T46B, chemically known as 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-acetate 17-(2-furaoate) but more generally known as dexamethasone acefurate, which bears US NIH Compound Identifier 168903. European Medicines Agency schedules Dexamethasone acefurate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07018MIG.

UNSPSC 51422332 Dexamethasone acefurate is a Commodity code that does not map to the recent state and local opportunities posted under it. Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI HHS0017013 gathers vendor capability information about direct-to-manufacturer prescription fulfillment programs—neither of which involves dexamethasone acefurate or corticosteroid pharmaceuticals. The mismatch suggests this code either sees minimal relevant recent procurement activity or has been incorrectly applied to opportunities in adjacent pharmaceutical and health-services categories.

The two posted opportunities span different procurement mechanisms and issuing-body types: Seminole County, a Florida county government, issued a competitive IFB with a response deadline of July 26, 2023, for consumable health-supply items on an annual-replenishment basis; the Texas Health and Human Services Commission, a state health agency, issued an RFI dated April 3, 2026, to explore vendor capacity for prescription-management program redesign. Geographic activity appears limited to Florida and Texas in the source data. Without additional opportunities aligned to the dexamethasone acefurate commodity scope, the code presents insufficient signal for targeting state and local procurement under its nominal description.